Glenn is a co-founder and Head of Discovery of Parthenon Therapeutics. Glenn is a hematologist/medical oncologist with over 20 years of clinical practice and drug development experience.
Prior to Parthenon, he's held positions of increasing scientific leadership responsibilities across the biotech industry (CEO of BioCurate, CSO of Xilio and TetraLogic, and NED at Oxford Biotherapeutics).
From 2002-2012, he was VP and Global Head of Hematology/Oncology Research at Amgen, California, responsible for 5 research sites; for supporting marketed products including the filgrastim and erythropoietin franchises (approx. US$4B pa and US$8B pa respectively). Over 25 clinical-stage molecules emerged from his group.
Glenn has highlighted the issue of research integrity and scientific reproducibility. He has made presentations on this subject including to President Obama's Science Council, the White House, US National Institutes of Health, US Academies of Science, US National Institute of Standards and Technology, Wellcome Trust, NHMRC, and numerous Universities, Research Institutes and companies.
His early research first described human G-CSF, then demonstrated that G-CSF-"mobilized" blood stem cells (so called "stem cell transplantation") hastened recovery versus bone marrow transplantation.
He was elected as the first Foreign Fellow to the American Society of Clinical Investigation (2000), the Association of American Physicians (2008), to the Research "Hall of Fame" at his alma mater, the Royal Melbourne Hospital (2014), to the Australian Academy of Health and Medical Sciences (2014). He has published over 200 papers (~25,000 citations; h-index 77; i10-index 188, source Google Scholar, August 2020). His TED-x seminar "The Complex Biology of Cancer" has >100,000 views.